Alkermes Inc. 's $100 million acquisition of 19.9% of Reliant Pharmaceuticals Inc. 's shares [See Deal] represents yet one more twist in the drug delivery company's evolution towards a product business. For most of its life, Alkermes has focused on proving its technologies, signing up drug-company partners, expanding its delivery menu (acquiring a number of businesses to do so) and, to the extent it's been able to, working on some products for its own account, taking generics and altering their formulation and release profiles to make them into more usable, more valuable drugs (it's developing, for example, a sustained-release implantable form of the anti-addiction medicine naltrexone, theoretically eliminating the compliance problem among addicts).
What Alkermes doesn't yet have, however, is any way to market such products. The old drug-delivery philosophy was to simply...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?